Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Avastin Clinical Benefit Trumps Anti-Tumor Effect In Glioblastoma, ODAC Says

Executive Summary

Demonstration of an anti-tumor effect is not essential for a brain cancer indication if clinical benefit is provided, FDA's Oncology Drugs Advisory Committee indicated March 31 in recommending accelerated approval of Genentech's Avastin to treat relapsed glioblastoma multiforme
Advertisement

Related Content

Avastin QoL Data In First-Line Glioblastoma Muddy Expansion Plans
ODAC Veterans Disagree On Value Of Public Hearing At Panel Meetings
Role of Newly Approved Avastin In Glioblastoma Divides Experts
Approvals & Regulatory Updates, In Brief
Avastin Needs Quality Of Life Data In Confirmatory Glioblastoma Trial – Cmte.
Avastin Needs Quality Of Life Data In Confirmatory Glioblastoma Trial – Cmte.
Avastin Advisory Committee To Assess Validity Of Objective Response Rate Endpoint
FDA Cancer Endpoint Guidance Abandons Placebos, Moves Beyond Survival
Schering-Plough's Temodar Clears FDA For First-Line Use In Glioblastoma
Gliadel Marketing For Newly-Diagnosed Glioma Will Highlight Survival Benefit

Topics

Advertisement
UsernamePublicRestriction

Register

PS050895

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel